NCT05236257View on ClinicalTrials.gov

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

September 13, 2022

Study Completion Date

September 13, 2022

Conditions
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene FusionInfantile Fibrosarcoma
Interventions
DRUG

Larotrectinib (Vitrakvi, BAY2757556)

Pediatric patients with IFS harboring an NTRK gene fusion.

DRUG

Standard of Care

Standard of care for the patients from the eligible external cohorts.

Trial Locations (1)

Unknown

Multiple Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05236257 - A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database | Biotech Hunter | Biotech Hunter